News & Publications

The 17th Annual MMIG Meeting ttok place on Friday, March 17th in New Orleans and over Zoom. The MCC Multi-center Merkel Interest Group is an international collection of clinicians, scientists, and trainees across various medical institutions who are dedicated to improving MCC patient care by studyi...

On March 22, 2023, the Food and Drug Administration granted accelerated approval to retifanlimab-dlwr (Zynyz, Incyte Corporation) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This agent joins avelumab and pembrolizumab as approved therapies for MCC. ...

This article from the Boston Globe tells the story of HIV activist and MCC patient, Stewart Landers, and his efforts to raise awareness of MCC. He has been an advocate for improved accessibility to treatment for HIV patients who are often excluded from potentially life-saving clinical trials.

We will be having our annual 2023 Multi-center Merkel Interest Group meeting on Friday, March 17th in New Orleans and over Zoom. The MCC Multi-center Merkel Interest Group is an international collection of clinicians, scientists, and trainees across various medical institutions who are dedicated to ...

Dear friends of Merkel cell carcinoma research, As we enter this season of gratitude and reflection, I would like to thank you for your partnership. I am pleased to share our annual holiday letter, which describes some of the progress that you have made possible this year. If you would like to conti...

Terry Bradshaw's recent diagnosis of Merkel cell carcinoma has brought some awareness of MCC to a larger number of people. This article, written by a journalist-physician, attempts to provide some background on his situation, as well as on MCC more broadly. Such information can clearly be useful for...

The immune stimulating drug combination called ‘ipi-nivo’ (IPIlimumab or Yervoy targets CTLA4 while NIVOlumab or Opdivo targets PD1) has an established role in melanoma, but less is known about using this double therapy in Merkel cell carcinoma. A major study published in the Lancet and led by K...

The University of Washington's Nghiem Lab held its annual Merkel CELLebration & Dinner on Monday, Sept. 12, 2022, at the UW Medicine Research Campus in Seattle’s South Lake Union neighborhood. Each year the Nghiem Lab hosts the event to share the latest advances in the treatment of Merkel cell car...

Several faculty, trainees and researchers representing UW Dermatology presented their research at the SID Annual Meeting in Portland, Oregon from May 18-21, 2022. Each year, the Society for Investigative Dermatology (SID)’s Annual Meeting invites a diverse group of researchers and clinicians, as w...

The UW Division of Dermatology hosted the 2nd International Symposium on Merkel Cell Carcinoma in Seattle, WA, from April 25-26, 2022. The two-day hybrid (in-person and virtual) event held at the Graduate Hotel brought together over 140 thought leaders, active investigators, faculty and trainees in ...